Skip Navigation

Disclosure of Advisory Roles and Certain Industry Support for Paths of Progress 2019

  • Dana-Farber is committed to ensuring the veracity of research conducted under its oversight and follows strict policies and procedures to ensure its research meets the highest ethical standards. Following is an overview of relevant board memberships, outside support, and significant advisory roles as reported by several physicians and researchers featured in the 2019 issue of Dana-Farber's Paths of Progress magazine.

    • Eric Fischer, PhD, is a founder and/or science advisory board member (SAB) and equity holder in C4 Therapeutics and Civetta Therapeutics. The Fischer lab receives or has received research funding from Astellas, Deerfield, and Novartis.
    • Irene Ghobrial, MD, has served as a consultant for Celgene, Janssen, Millennium, Novartis, Onyx, Sanofi, and Takeda.
    • Nathanael Gray, PhD, is a founder, science advisory board member (SAB), and equity holder in B2S, C4, Gatekeeper, Petra, Soltego, and Syros. He is a member of the fiduciary board of Soltego. The Gray lab receives or has received research funding from Astellas, Deerfield, Her2llc, Jansen, Kinogen, Novartis, Sanofi, Taiho, and Takeda.
    • David Livingston, MD, is a consultant to Constellation Pharma, Nextechinvest, and Novartis. Furthermore, his laboratory participated in research on CDK 4/6 during the 90s and again, briefly, during the early 2000s. None of that work nor any of his work with the above-noted companies has focused on any of the known CDK 4/6 clinical inhibitors or related compounds.
    • Erica Mayer, MD, MPH, has served as a consultant for Context Therapeutics, Eisai, Lilly, Novartis, and Pfizer. Her laboratory receives research support from Myriad and Pfizer.
    • Rizwan Romee, MD, is a consultant for Kiadis Pharma.
    • Geoffrey Shapiro, MD, PhD, has received research funding from Eli Lilly, Merck, Merck KGaA/EMD-Serono, and Sierra Oncology. He has served on advisory boards for Almac, Angiex, Astex, Bayer, Bicycle Therapeutics, Cybrexa Therapeutics, Daiichi Sankyo, Eli Lilly, Fusion Pharmaceuticals, G1 Therapeutics, Ipsen, Merck KGaA/EMD-Serono, Pfizer, Roche, and Sierra Oncology. Dana-Farber Cancer Institute has received funding from Array BioPharma and Pfizer for the conduct of investigator-initiated clinical trials of palbociclib led by Dr. Shapiro. He also has a pending patent related to his work on CDK4/6 inhibition entitled "Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition." This application claims the benefit of priority under 35 U.S.C. x 119(e) to U.S. Provisional Application No. 62/538,319, filed July 28, 2017.
    • Peter Sicinski, MD, PhD, was a consultant at Genovis, Guidepoint, Novartis, ORIC Pharmaceuticals, and The Planning Shop. His lab receives and has received research funding from Novartis.
    • Loren Walensky, MD, PhD, is a scientific advisory board member and consultant for Aileron Therapeutics.

Posted on May 24, 2019

  • Media Contacts

    For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to media@dfci.harvard.edu.

  • Request a Publication

    Receive by mail the current issue of a Dana-Farber publication by completing this request form.